Back to results
US 2019/0194087 A1Published application
Preparation of 212pb labeled monoclonal antibodies
AssigneeSciencons AS
InventorRoy Hartvig Larsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to the generation of lead-212 for therapeutic use. Specifically, are methods related to the generation of lead-212 based radio labelled proteins, such as radioimmunoconjugates, embodiments of the present invention.
Claims21
A method for generating a radionuclide labeled protein, the method comprising:
- a) providing an aqueous solution comprising 224Ra and 212Pb, and an aqueous solution comprising a protein conjugated with a chelator,
- b) mixing and incubating the solutions provided in a) to provide a reaction solution comprising a radionuclide labeled protein,
- c) purifying the reaction solution by gel filtration chromatography, and
- d) recovering the radionuclide labelled protein from the purification in step c).
1 more element
2-20. (canceled)
A kit for the generation of a radionuclide labeled protein comprising:
- (i) an aqueous solution comprising 224Ra and 212Pb,
- (ii) an aqueous solution comprising a protein conjugated with a chelator,
- (ii) gel filtration media, and
- (iv) optionally, instructions for the generation of a radionuclide labeled protein.
1 more element
A radionuclide labelled protein composition comprising:
- 212Pb conjugated to a protein,
- 212Bi conjugated to a protein,
- 0.1%-2% free 224Ra,
- less than 50% free 212Bi, and
- less than 20% free 212Pb.
2 more elements
Dependencies are inferred from the claim text.